A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (Generation S2)
Diseases of the Nervous System | Alzheimer's Disease
What is the purpose of this trial?
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
- Ages60 - 75 years
- Trial withNovartis Pharmaceuticals
- Start Date03/22/2018
- End Date07/29/2024
- Last Updated05/23/2018
- Study HIC#2000021334